A team of scientists at the Monash Biomedicine Discovery Institute has done a study involving a novel therapy that uses stem cells for the treatment of chronic asthma. The team used induced pluripotent stem cell-derived mesenchymal stem cells on a dummy model of experimental asthma. Pluripotent stem cells have the potency to generate directly into adult cells, thus, they differentiate into various types of tissues. To know more about the uses of stem cells you can log on to https://www.lifecell.in/about-stem-cells. So the team at Monash University based the research on the regenerative properties of the mesenchymal cells that could regenerate the damaged lung tissue.
Professor Christian Samuel the lead professor of the research wing and Dr. Simon Royce were extensively working on three different preclinical stages that affect the chronic asthmatics. The first being allergic airway disease, the next being an inflammatory phase and airway modeling. Airway remodeling only occurs in the case of a prolonged inflammation of lung tissue. The last stage researched was airway hyperresponsiveness and this is the condition that manifests itself as a full blown asthmatic episode with typical symptoms such as wheeze. All these 3 stages were treated and tested with mesenchymal stem cells.
The study found that mesenchymal cells efficiently reduced inflammation, signs of airway remodeling and also completely reversed the lung fibrosis. The hyperresponsiveness also normalized, when the stem cells were delivered intranasally. Thus the team concluded that this stem cell therapy can be either used as a stand-alone therapy or as an adjunct therapy for the suffering asthmatic patients, who were immune to steroidal therapy and did not respond to corticosteroids any longer. Thus, this study was published by the team at the FASEB Journal under the treatment for allergic chronic obstructive airway diseases.
This research was mainly intended for the treatment of cystic fibrosis, which is the hardening of the lung parenchymal cells along with scarring. There is no other effective treatment for patients with this condition. Fortunately, stem cell treatment proved effective and could fully reverse the scarred damaged lung tissue. The cellular dysfunction also slowly began to clear up when combined with anti-scarring drugs. The cells regenerated were excellent in function and enhanced the breathing in patients, thus symptomatic relief was also witnessed after the stem cell therapy. After this fresh and promising innovation, future studies are also being conducted using mesenchymal stem cells with or without the combination of corticosteroids, offering hope to asthma patients across the globe.